Overview: daraxonrasib Extends Survival in Metastatic Pancreatic Cancer in the RASolute 302 Phase III Trial

Written by

in

In the randomized Phase III RASolute 302 trial, daraxonrasib extended the median overall survival of 500 previously treated patients with metastatic pancreatic cancer from 6.7 months to 13.2 months, reduced the risk of death by 60%, with an HR of 0.40. The objective response rate confirmed in the ITT population was 31.6%.

Source:BIOENGINEER.ORG · Read the original

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *